These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 12452732)
1. Minimising the long-term adverse effects of childhood leukaemia therapy. Langebrake C; Reinhardt D; Ritter J Drug Saf; 2002; 25(15):1057-77. PubMed ID: 12452732 [TBL] [Abstract][Full Text] [Related]
2. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809 [TBL] [Abstract][Full Text] [Related]
3. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide. Estlin EJ; Yule SM; Lowis SP Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927 [TBL] [Abstract][Full Text] [Related]
4. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. Ronghe M; Burke GA; Lowis SP; Estlin EJ Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926 [TBL] [Abstract][Full Text] [Related]
5. An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Zerra P; Cochran TR; Franco VI; Lipshultz SE Expert Opin Pharmacother; 2013 Aug; 14(11):1497-513. PubMed ID: 23705955 [TBL] [Abstract][Full Text] [Related]
6. [Current trends in the chemotherapy of cancer]. Silva-Sosa M Gac Med Mex; 1974 May; 107(5):469-87. PubMed ID: 4602758 [No Abstract] [Full Text] [Related]
8. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J; J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397 [TBL] [Abstract][Full Text] [Related]
9. Exposure to anthracyclines during childhood causes cardiac injury. Lipshultz SE Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284 [TBL] [Abstract][Full Text] [Related]
10. Minimizing cardiac toxicity in children with acute myeloid leukemia. Narayan HK; Getz KD; Leger KJ Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355 [TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659 [TBL] [Abstract][Full Text] [Related]
12. Cardiac complications in childhood cancer survivors treated with anthracyclines. Franco VI; Lipshultz SE Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717 [TBL] [Abstract][Full Text] [Related]
13. Anthracycline cardiotoxicity in childhood. Ruggiero A; Ridola V; Puma N; Molinari F; Coccia P; De Rosa G; Riccardi R Pediatr Hematol Oncol; 2008 Jun; 25(4):261-81. PubMed ID: 18484471 [TBL] [Abstract][Full Text] [Related]
14. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia. Messinger Y; Uckun FM Leuk Lymphoma; 1999 Aug; 34(5-6):415-32. PubMed ID: 10492065 [TBL] [Abstract][Full Text] [Related]
15. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607 [TBL] [Abstract][Full Text] [Related]
16. The effects of leukemia and lymphoma chemotherapy on hematopoietic cells. Brunning RD Am J Med Technol; 1973 May; 39(5):165-74. PubMed ID: 4701364 [No Abstract] [Full Text] [Related]
17. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia]. Thomas X; Cannas G; Chelghoum Y; Gougounon A Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115 [TBL] [Abstract][Full Text] [Related]
18. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; CalabrĂ² R Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628 [TBL] [Abstract][Full Text] [Related]
19. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study. Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397 [TBL] [Abstract][Full Text] [Related]
20. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL; Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]